Nelarabine

NEW!

Benefits at a glance

  • Niche Product
  • High Flexibility with the business model
  • Dossier already submitted in the US

Product details

Indication:

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)

Strengths

5 mg / ml

Dosage form

Vial / Injection

API

Nelarabine

Dossier

available

Turnover

7 Mio. € (IQVIA 2021 – EU)

Status

  • Development Kick-off
  • Formulation Development
  • Prototype
  • Pilot BE
  • Scale Up
  • Pivotal BE
  • 6 M Stability
  • Dossier
  • EU-Approval

Summary

With our Nelarabine-Dossier, we can offer access to a dossier, which has been successfully submitted in the US (Aug. ’22).

The dossier can be shortly updated to meet EU-standards, as the supply chain (manufacturing site and API-supplier) are EU-GMP certified.

With approximately 20.000 yearly diagnoses of T-Cell leukemia, our Nelarabine-Dossier can provide patients with an adequate treatment option and unlock significant market potential with strong year over year growth rates (> 50 %) and limited competition.

 

Your Contact

Heike Sagi

Heike Sagi

Business Development & Licensing
Senior Director

Midas Pharma GmbH
Rheinstraße 49
55218 Ingelheim
Germany
  • Disclaimer

    The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.

     

Share this page